

INTERNATIONAL UNION OF PURE  
AND APPLIED CHEMISTRY

CHEMISTRY AND HUMAN HEALTH DIVISION  
MEDICINAL CHEMISTRY SECTION

**GLOSSARY OF TERMS USED IN  
MEDICINAL CHEMISTRY**

(IUPAC Recommendations 1998)

*Prepared for publication by*

C. G. WERMUTH<sup>1</sup> (CHAIRMAN),  
C. R. GANELLIN<sup>2</sup>, P. LINDBERG<sup>3</sup> AND L. A. MITSCHER<sup>4</sup>

<sup>1</sup>Faculté de Pharmacie, Université Louis Pasteur, Strasbourg, France

<sup>2</sup>University College London, London, UK

<sup>3</sup>Astra Hässle AB, Mölndal, Sweden

<sup>4</sup>School of Pharmacy, University of Kansas, Lawrence, Kansas, USA

Membership of the Section during the period (1992–1995) when this report was prepared was as follows:

*President:* J. G. Topliss (USA); *Vice-President:* N. Koga (Japan); *Past-President:* C. G. Wermuth (France); *Secretary:* W. D. Busse (Germany); *Titular members:* C. R. Ganellin (U.K.); L. A. Mitscher (USA); *Co-opted members:* P. Anderson (USA); P. R. Andrews (Australia); W. A. Denny (New Zealand); W. Granick (Russia); Y. Guindon (Canada); C. A. G. Haasnoot (The Netherlands); J. Ide (Japan); R. Imhof (Switzerland); P. Lindberg (Sweden); G. Tarzia (Italy); R. S. Xu (China); *National Representatives:* A. O. M. Stoppani (Argentina); E. J. Barreiro (Brazil); A. Again (Bulgaria); J. Krepelka (Czechoslovakia); E. K. Pohjala (Finland); A. Monge Vega (Spain).

---

*Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgement, with full reference to the source along with use of the copyright symbol ©, the name IUPAC and the year of publication are prominently visible. Publication of a translation into another language is subject to the additional condition of prior approval from the relevant IUPAC National Adhering Organization.*

# Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)

*Abstract:* The objective of the glossary is to provide in a single document a consistent terminology and concise definitions of terms covering the various aspects of medicinal chemistry. This was felt necessary with regard to the rapid changes occurring in medicinal chemistry and also by the need to establish international definition standards. Effectively the possibility exists that in different countries certain terms may not have the same meaning, in such a case the creation of an internationally accepted definition is particularly justified.

A Working Party belonging to the IUPAC Section on Medicinal Chemistry has therefore been assembled which prepared the present glossary. Concise but sufficiently explanatory definitions have been formulated for about one hundred commonly employed terms which can be considered of particular interest to the medicinal chemistry community. The glossary has been compiled in part from definitions proposed by the Working Party in part from earlier IUPAC glossaries and in part from well-accepted definitions taken from the literature but which were sometimes published in journals or books that may not be readily accessible.

## ALPHABETICAL ORDERED ENTRIES

The glossary has been compiled in part from definitions proposed by the Working Party and in part from well-accepted definitions taken from the literature. In most cases, definitions given here are for specific areas of medicinal chemistry. Some definitions taken from the Glossary for Chemists of Terms Used in Biotechnology (*Pure Appl. Chem.*, 1992, **64**, 143–168) were also included, eventually in a slightly modified form; they are identified by an asterisk\*. Others, which appear in the Glossary on Computational Drug Design (*Pure Appl. Chem.*, 1997, **69**, 1137–1152) and in Glossary for Chemists of terms used in Toxicology (*Pure Appl. Chem.* 1993, **65**, 2003–2122), are identified by a double\*\* and a triple\*\*\* asterisk respectively.

### Active transport\*

**Active transport** is the carriage of a solute across a biological membrane from low to high concentration that requires the expenditure of (metabolic) energy.

### Address-message concept

**Address-message concept** refers to compounds in which part of the molecule is required for binding (address) and part for the biological action (message).

### ADME

Abbreviation for **Absorption, Distribution, Metabolism, Excretion**. (See also **Pharmacokinetics; Drug disposition**).

### Affinity

**Affinity** is the tendency of a molecule to associate with another. The **affinity** of a **drug** is its ability to bind to its biological target (**receptor, enzyme, transport system, etc.**) For pharmacological **receptors** it can be thought of as the frequency with which the **drug**, when brought into the proximity of a **receptor** by diffusion, will reside at a position of minimum free energy within the force field of that **receptor**.

For an **agonist** (or for an **antagonist**) the numerical representation of **affinity** is the reciprocal of the equilibrium dissociation constant of the ligand-**receptor** complex denoted  $K_A$ , calculated as the rate constant for offset ( $k_{-1}$ ) divided by the rate constant for onset ( $k_1$ ).

### **Agonist\*\*\***

An **agonist** is an endogenous substance or a **drug** that can interact with a **receptor** and initiate a physiological or a pharmacological response characteristic of that **receptor** (contraction, relaxation, secretion, **enzyme** activation, etc.).

### **Allosteric binding sites**

**Allosteric binding sites** are contained in many **enzymes** and **receptors**. As a consequence of the binding to **allosteric binding sites**, the interaction with the normal ligand may be either enhanced or reduced.

### **Allosteric enzyme\***

An **allosteric enzyme** is an **enzyme** that contains a region to which small, regulatory molecules ("effectors") may bind in addition to and separate from the substrate binding site and thereby affect the catalytic activity.

On binding the effector, the catalytic activity of the **enzyme** towards the substrate may be enhanced, in which case the effector is an activator, or reduced, in which case it is a de-activator or inhibitor.

### **Allosteric regulation**

**Allosteric regulation** is the regulation of the activity of **allosteric enzymes**. (See also **Allosteric binding sites**; **Allosteric enzymes**).

### **Analog**

An **analog** is a **drug** whose structure is related to that of another **drug** but whose chemical and biological properties may be quite different. (See also **Congener**).

### **Antagonist\*\*\***

An **antagonist** is a **drug** or a compound that opposes the physiological effects of another. At the **receptor** level, it is a chemical entity that opposes the **receptor**-associated responses normally induced by another bioactive agent.

### **Antimetabolite\*\*\***

An **antimetabolite** is a structural **analog** of an intermediate (substrate or **coenzyme**) in a physiologically occurring metabolic pathway that acts by replacing the natural substrate thus blocking or diverting the biosynthesis of physiologically important substances.

### **Antisense molecule**

An **antisense molecule** is an **oligonucleotide** or **analog** thereof that is complementary to a segment of RNA (ribonucleic acid) or DNA (deoxyribonucleic acid) and that binds to it and inhibits its normal function.

**Autacoid**

An **autacoid** is a biological substance secreted by various cells whose physiological activity is restricted to the vicinity of its release; it is often referred to as local **hormone**.

**Autoreceptor**

An **autoreceptor**, present at a nerve ending, is a **receptor** that regulates, via positive or negative feedback processes, the synthesis and/or release of its own physiological ligand. (See also **Heteroreceptor**).

**Bioassay\*\*\***

A **bioassay** is a procedure for determining the concentration, purity, and/or biological activity of a substance (e.g., vitamin, **hormone**, plant growth factor, antibiotic, **enzyme**) by measuring its effect on an organism, tissue, cell, **enzyme** or **receptor** preparation compared to a standard preparation.

**Bioisostere**

A **bioisostere** is a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound. The bioisosteric replacement may be physicochemically or topologically based. (See also **Isostere**)

**Bioprecursor prodrug**

A **bioprecursor prodrug** is a **prodrug** that does not imply the linkage to a carrier group, but results from a molecular modification of the active principle itself. This modification generates a new compound, able to be transformed metabolically or chemically, the resulting compound being the active principle.

**Biotransformation**

**Biotransformation** is the chemical conversion of substances by living organisms or **enzyme** preparations.

**CADD**

See **Computer-assisted drug design**

**Carrier-linked prodrug (Carrier prodrug)**

A **carrier-linked prodrug** is a **prodrug** that contains a temporary linkage of a given active substance with a transient carrier group that produces improved physicochemical or pharmacokinetic properties and that can be easily removed *in vivo*, usually by a hydrolytic cleavage.

**Cascade prodrug**

A **cascade prodrug** is a **prodrug** for which the cleavage of the carrier group becomes effective only after unmasking an activating group.

**Catabolism\*\*\***

**Catabolism** consists of reactions involving endogenous organic substrates to provide chemically available energy (e.g., ATP) and/or to generate metabolic intermediates used in subsequent anabolic reactions.

**Catabolite**

A **catabolite** is a naturally occurring **metabolite**.

**Clone\***

A **clone** is a population of genetically identical cells produced from a common ancestor. Sometimes, "**clone**" is also used for a number of recombinant DNA (deoxyribonucleic acid) molecules all carrying the same inserted sequence.

**Codon\***

A **codon** is the sequence of three consecutive **nucleotides** that occurs in mRNA which directs the incorporation of a specific amino acid into a protein or represents the starting or termination signals of protein synthesis.

**Coenzyme**

A **coenzyme** is a dissociable, low-molecular weight, non-proteinaceous organic compound (often **nucleotide**) participating in enzymatic reactions as acceptor or donor of chemical groups or electrons.

**Combinatorial synthesis**

**Combinatorial synthesis** is a process to prepare large sets of organic compounds by combining sets of building blocks.

**Combinatorial library**

A **combinatorial library** is a set of compounds prepared by combinatorial synthesis.

**CoMFA**

See **Comparative Molecular Field Analysis**

**Comparative Molecular Field Analysis (CoMFA)\*\***

**Comparative molecular field analysis (CoMFA)** is a **3D-QSAR** method that uses statistical correlation techniques for the analysis of the quantitative relationship between the biological activity of a set of compounds with a specified alignment, and their three-dimensional electronic and steric properties. Other properties such as hydrophobicity and hydrogen bonding can also be incorporated into the analysis. (See also **Three-dimensional Quantitative Structure-Activity Relationship [3D-QSAR]**).

**Computational chemistry\*\***

**Computational chemistry** is a discipline using mathematical methods for the calculation of molecular properties or for the simulation of molecular behaviour.

**Computer-assisted drug design (CADD)\*\***

**Computer-assisted drug design** involves all computer-assisted techniques used to discover, design and optimize biologically active compounds with a putative use as **drugs**.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.